Transgene Stock

Transgene EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Transgene (TNG.PA) as of Jul 26, 2026 is -8.51. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -6.28 — a change of 35.52% (lower).

EV/FCF

-8.51

YoY

35.52%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene is 2026 -8.51 . EV/FCF (Enterprise Value to Free Cash Flow) of Transgene was 2025 -6.28 . It decreases by 35.52% lower compared to the previous year.
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene is -8.51 in 2026.

Access this data via the Eulerpool API

Valuation — Transgene

All Key Metrics — Transgene